Key facts
- Axio BioPharma’s last known valuation is $10.0M (Jan 2025).
- It has raised $3.1M; the latest was Seed Round ($3.0M) in Jan 2025.
- Notable investors include Silicon Valley Advantage.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Axio BioPharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Axio BioPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Axio BioPharma
Operator of a contract development and manufacturing company intended to transform biopharmaceutical manufacturing. The company's product leverages artificial intelligence to accelerate the development of mammalian-expressed recombinant proteins and offers services such as construct optimization, expression process development, purification process development, research-grade manufacturing, GMP (good manufacturing practice) manufacturing, enabling patients to get the enhanced process from the laboratory.
- Sector
- Healthcare
- HQ
- Madison, WI, United States
- Founded
- 2024
- Employees
- 9
- Website
- axiobiopharma.com/
- Ownership
- Privately Held (backing)
Axio BioPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axio BioPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axio BioPharma in its N-PORT filings yet. We sweep new filings monthly.